Therapeutic perspectives for melatonin agonists and antagonists.
about
New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitorsTherapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapyInfluence of photoperiod on hormones, behavior, and immune function.Pharmacological modulation of circadian rhythms: a new drug target in psychotherapeutics.Effect of Melatonin on the Extracellular-Regulated Kinase Signal Pathway Activation and Human Osteoblastic Cell Line hFOB 1.19 Proliferation.Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine TumoursCirculating melatonin and the risk of breast and endometrial cancer in women.Quinone reductase 2 as a promising target of melatonin therapeutic actions.Original Design of Fluorescent Ligands by Fusing BODIPY and Melatonin Neurohormone.Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.In cerebrovascular circadian rhythms, EETs keep the beat. Focus on "Rhythmic expression of cytochrome P450 epoxygenases CYP4x1 and CYP2c11 in the rat brain and vasculature".Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.Mechanisms of N-methyl-D-aspartate receptor inhibition by melatonin in the rat striatum.
P2860
Q28238260-00A8DE0E-F9C3-43CE-A3CF-0FD4935E1759Q28266443-213E2BA4-A324-4985-B5AB-AD5FA8F542CCQ35115826-5D3E342D-8C4A-4126-85C6-B69DFAA4A271Q35680557-CAF44DC6-93DA-4906-B904-7B11F783E246Q35723300-B1A42BA3-B5D0-41EC-A284-161DFD9A6925Q36162902-C7834D21-FEAE-4D8D-99F1-42FA36ECC47DQ37328085-BDD64094-1E1F-425D-A31B-DCD76ABD99C4Q38606734-362697BC-1671-4C4B-89EF-B5BEE10E707BQ39781710-4B033D11-2E9E-42FA-BC99-6BFBC6006F42Q42156506-A9DEF8A6-FE59-4E7F-9DBC-C0642F5504B1Q42576597-89F2305B-9C77-481F-907A-5B56E0CF7149Q42709930-9D665E17-C984-4BCD-BF1B-03EA7905A04DQ45175176-21AE4FB3-BC9D-4B5F-A617-0E2B9993C7F7Q45177776-5A88C251-189C-46ED-A11C-F1FC17E866D5
P2860
Therapeutic perspectives for melatonin agonists and antagonists.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic perspectives for melatonin agonists and antagonists.
@ast
Therapeutic perspectives for melatonin agonists and antagonists.
@en
type
label
Therapeutic perspectives for melatonin agonists and antagonists.
@ast
Therapeutic perspectives for melatonin agonists and antagonists.
@en
prefLabel
Therapeutic perspectives for melatonin agonists and antagonists.
@ast
Therapeutic perspectives for melatonin agonists and antagonists.
@en
P2093
P50
P1476
Therapeutic perspectives for melatonin agonists and antagonists
@en
P2093
P304
P356
10.1046/J.1365-2826.2003.01016.X
P577
2003-04-01T00:00:00Z